A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. - Wikidata - wikimedia - TriplyDB

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis.

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis.

http://www.wikidata.org/entity/Q35015986

about

Treatment for familial amyotrophic lateral sclerosis/motor neuron disease A comprehensive review of amyotrophic lateral sclerosis Therapeutic neuroprotective agents for amyotrophic lateral sclerosis Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS?The PRO-ACT database: design, initial analyses, and predictive features AMPA receptor synaptic plasticity induced by psychostimulants: the past, present, and therapeutic future Potential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis.Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and research.The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice.ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients Talampanel reduces the level of motoneuronal calcium in transgenic mutant SOD1 mice only if applied presymptomatically Moving toward a predictive and personalized clinical approach in amyotrophic lateral sclerosis: novel developments and future directions in diagnosis, genetics, pathogenesis and therapies Current Therapy of Drugs in Amyotrophic Lateral Sclerosis.Selection and Prioritization of Candidate Drug Targets for Amyotrophic Lateral Sclerosis Through a Meta-Analysis Approach.Reactive astrocytes as therapeutic targets for CNS disorders.Emerging drugs for amyotrophic lateral sclerosis.How can we improve clinical trials in amyotrophic lateral sclerosis?Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis.AMPA receptors as drug targets in neurological disease--advantages, caveats, and future outlook.New AMPA antagonists in epilepsy.Neuroprotection in multiple sclerosis: a therapeutic approach.The discovery and development of perampanel for the treatment of epilepsy.Predicting success: optimizing phase II ALS trials for the transition to phase III.Assessment of disease progression and functional benefit in neurodegenerative disease: can we tell the difference?Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs.Transcriptional analysis reveals distinct subtypes in amyotrophic lateral sclerosis: implications for personalized therapy.A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies.Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis.Strength Testing in Motor Neuron Diseases.Mechanism of inhibition of the GluA2 AMPA receptor channel opening by talampanel and its enantiomer: the stereochemistry of the 4-methyl group on the diazepine ring of 2,3-benzodiazepine derivatives.The MITOS system predicts long-term survival in amyotrophic lateral sclerosis.Shortcomings in the Current Amyotrophic Lateral Sclerosis Trials and Potential Solutions for Improvement.Motoneuron Disease: Clinical.Synaptic dysfunction and altered excitability in C9ORF72 ALS/FTD.Opioid and Psychostimulant Plasticity: Targeting Overlap in Nucleus Accumbens Glutamate Signaling.Difference in chronological changes of outcome measures between untreated and placebo-treated patients of spinal and bulbar muscular atrophy.The El Escorial criteria: Strengths and weaknesses CDP-choline is not protective in the SOD1-G93A mouse model of ALS Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis

P2860

Q24241570-B9DE8C50-4690-456B-969D-9EF88B2EE5FC Q26775401-EDC14276-F6A1-4DAE-824E-B11402CF30A9 Q27015029-129FFA5E-4450-47DB-96C2-FD9AF56514A8 Q28649394-CD7D039C-AF5F-4BBA-8C83-CA3F1901EBE1 Q28651661-CDC57DF1-AAB0-48E0-B1ED-EBC9A1BCA405 Q33995795-5DC09289-76D0-492F-AB70-D452F060F1E2 Q34276055-B3993FB5-6C8F-42F1-AFAB-973E2F26DBBA Q34401653-D58B6D38-EB14-4594-8A9A-EE0798AADD00 Q34532115-B0AFDF16-890C-422A-A4A4-2B6B0E252E22 Q34554820-5F4CADFE-09BB-40E5-8722-CF56D6276DA9 Q34699979-1CE1D517-81DA-4752-A2A1-D62F970CA5DA Q35595854-B9A340CB-422D-4255-92D2-61E0AF36CFB9 Q36117639-B4DA941F-9139-48A2-96B0-2A1A8B8473B3 Q36925891-6B524CC4-265D-4B45-A127-893CF2B28AF3 Q37712723-C8348A61-285C-4DCC-8EA8-9AC383560F4E Q37794398-448332C1-A6C8-4B70-B4CC-676CA9FC904B Q37909351-A2C4E67D-91FE-47B9-8E72-B9A6EE6D3551 Q37938694-8121C473-608D-4607-892A-88CFF255A43D Q37981224-4C6A4BDA-3062-44E3-80A2-9FE0198D9A71 Q38019570-72DEFF79-057E-4E0A-BB29-F469EDDD05E2 Q38025721-F8F5D4A7-57D5-45E9-A50C-317DC71FA3A3 Q38129748-D586EC9C-C997-4921-A1CE-49B662C64785 Q38190084-A9F6B496-2771-4736-AE90-93B63459DD2C Q38192690-738276E8-9A10-4302-9E58-B20D946F5D8C Q38219475-B5C6174D-FAA1-4FD4-BEC0-59D496D38833 Q38223292-200A3B4E-DF58-4735-A595-441BD2E24ECD Q38542939-99684AC5-BC35-41EF-8934-D8DF6FA7CF17 Q38573829-1AE01640-F964-41D2-94C6-1FB1D3518FFD Q38741121-52D91B50-DE71-4E56-929B-4C9DBD3CE9B9 Q38947721-D0F404DC-A13E-4886-9ED5-40921552DEF2 Q39931409-927D10A9-B2C0-4E03-A9CF-FAEF5E29B076 Q41052218-822D2D04-5133-4269-8CF5-5F90400D3D14 Q42369773-D414D08D-946E-43CA-A024-45AF8622AB42 Q45869420-F7D93638-C1F0-4D67-8D7A-752050CF1DD7 Q49905442-4A67AE29-DEE3-4344-9140-C1FDC8323543 Q50023605-86866281-5D6A-448B-8129-0DB3D84BEA63 Q54293402-8BD24679-3D94-4807-9976-FAFA3BC4606C Q57911703-B0C471EB-98B0-440B-8689-C2EB8104111F Q58181343-AE0E56B3-1FFF-4DFF-9AF1-09D49F104154 Q58250570-8F40CBA0-4BE2-4663-8D72-7B22AC2A65D3

P2860

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis.

http://www.wikidata.org/entity/Q35015986

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis.

@ast

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis.

@en

type

label

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis.

@ast

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis.

@en

prefLabel

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis.

@ast

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis.

@en

P1433

Q35015986-647248BA-947E-49A2-AA9C-EDE800140ADF

P1476

Q35015986-8AF2B8AC-6CD4-4B25-A07D-887F125E7F18

P2093

Q35015986-37A26139-2657-462A-B4E4-63639F2E46EC

Q35015986-76F7CA77-6F8B-44D3-97AB-B264A243C271

Q35015986-8AE44B49-2B2C-492C-B33C-E8A30B3FEA8A

Q35015986-8E8E0EBC-13E6-4AC3-A2FD-3231218D54B6

Q35015986-94D11C6E-CF60-41C5-9BBD-698D7D7CE1FB

Q35015986-9ECD8AE6-C235-4703-877F-7055F4C69DE8

Q35015986-A0E8DD8E-C1CB-4FBB-B3F0-0492E33E55C3

Q35015986-C647215A-0C6B-4AA9-AAF3-DB892E0BBB54

Q35015986-D98E61A8-EAD1-4FC6-A4D8-EC8DB9CF2ECE

P2860

Q35015986-1FE643CC-8163-4BB4-850C-A40C69AB8CD9

Q35015986-3CF46CA9-8284-4B4F-AE77-674B13B7277B

Q35015986-4279DC5E-4AF2-4C60-89CD-EE7538795BE9

Q35015986-51D800B6-58FB-4255-9A78-E0AE3EEBD79B

Q35015986-61508E12-4E63-4352-8885-90A053B46C8B

Q35015986-69829143-43DC-4D47-B55D-CCF1990153E3

Q35015986-6F63CFE9-196B-4CD3-BC44-B43E2C3FDB88

Q35015986-85A18BAB-6F15-4EDA-A468-AC65A322F166

Q35015986-8C65C3ED-7F28-49BF-970E-9598B91E2068

Q35015986-B59CCC89-89B0-434C-9474-D65E535A6513

P304

Q35015986-34672FE5-FB2D-4F84-808D-873330BD7070

P31

Q35015986-2D74A813-79C6-4F05-AA00-5F83216C9EBE

P356

Q35015986-839A3E52-FB79-4690-951C-1562D89A0AB6

P433

Q35015986-EF60062C-40D5-415F-981A-83B46F80BB37

P478

Q35015986-D7D9E1DA-538E-4F76-9CE6-166579A63E1D

P577

Q35015986-1D2E3797-96B2-4375-92F0-5F2FCB24EB4B

P698

Q35015986-41D5D8EA-E8F4-4261-9738-47AA86BA6BC9

P921

Q35015986-6F5C98E4-086E-4541-8639-1899F2470826

Q35015986-E73BE068-32B6-49DB-88EA-8991A24358A1

P356

17482960903307805

P1433

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

P1476

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis.

@en

P2093

Amy S Chappell

http://www.w3.org/2001/XMLSchema#string

Jeffrey D Rothstein

http://www.w3.org/2001/XMLSchema#string

Jeremy Shefner

http://www.w3.org/2001/XMLSchema#string

John S Bjerke

http://www.w3.org/2001/XMLSchema#string

Lisa Haas

http://www.w3.org/2001/XMLSchema#string

Lora Clawson

http://www.w3.org/2001/XMLSchema#string

Robert M Pascuzzi

http://www.w3.org/2001/XMLSchema#string

Roy Tamura

http://www.w3.org/2001/XMLSchema#string

Vinay Chaudhry

http://www.w3.org/2001/XMLSchema#string

P2860

From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS

Mutations in the glutamate transporter EAAT2 gene do not cause abnormal EAAT2 transcripts in amyotrophic lateral sclerosis

Talampanel a non-competitive AMPA-antagonist attenuates caspase-3 dependent apoptosis in mouse brain after transient focal cerebral ischemia.

Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis.

Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression.

Ca(2+)-permeable AMPA receptors and selective vulnerability of motor neurons.

Current hypotheses for the underlying biology of amyotrophic lateral sclerosis.

Protection from fatal viral encephalomyelitis: AMPA receptor antagonists have a direct effect on the inflammatory response to infection

Crosstalk between astrocytes and motor neurons: what is the message?

Altered expression of the glutamate transporter EAAT2b in neurological disease.

P304

266-271

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/17482960903307805

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19961264

http://www.w3.org/2001/XMLSchema#string

P921

amyotrophic lateral sclerosis

phase II clinical trial